# Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)

> **NCT00378599** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 125 (actual)

## Conditions studied

- Liver Transplantation
- Hepatitis C, Chronic
- Liver Cirrhosis

## Interventions

- **DRUG:** Combination of (a) pegylated interferon alfa-2b and (b) rebetol

## Key facts

- **NCT ID:** NCT00378599
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2017-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00378599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00378599, "Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00378599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*